Syngulon announces the issuance by the USPTO of a first patent (US patent 9,333,227)

LIEGE, Belgium - May 14, 2016 - PRLog -- Syngulon announces the issuance by the USPTO of US patent 9,333,227 covering the use of bacteriocin/immunity for controlled growth of microorganisms.

On May 10, 2016 the USPTO issued a patent to Syngulon for the use of bacteriocin/immunity in any bacteria, yeast or algae for controlled growth of microorganisms.

This issued patent, based on an application filed in August 2013, is part of a new worldwide patent portfolio developed by Syngulon and available for licensing in all fields of use on a non-exclusive base.

The inventor of this patent is Dr Philippe Gabant, Founder and Chief Scientific Officer of Syngulon, one of the pioneers in the development of selection technologies. Dr Philippe Gabant is co-inventor of US patents 5,910,438 / 6,180,407 / 7,176,029 licensed on an exclusive base to Invitrogen for the selection of recombinant plasmids. Dr Philippe Gabant is also co-inventor of US patent 8,470,580 for the production of recombinant protein that has been licensed on non-exclusive base to Sanofi Pasteur, GSK and Merck.

This new patent of Syngulon, US 9,333,227, covers "a system for controlling growth of microbial organisms in a culture medium comprising a genetically engineered microbial cell […] "comprising" […] "nucleic acid sequence encoding a secreted bacteriocin which controls the growth of a second microbial cell, said secreted bacteriocin capable of inhibiting or preventing reproduction of said genetically engineered microbial cell in the absence of a cell immunity modulator that confers resistance to said secreted bacteriocin" […] "wherein said genetically engineered microbial cell is selected from the group consisting of bacteria, yeast, and algae."

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&...

About Syngulon

Syngulon is a Synthetic Biology startup focusing on microbial fermentation technologies for bio-based products. Syngulon is targeting three industries: Environment (waste management, water cycle management), Energy (e.g. biofuel), Biobased products (e.g. to replace chemicals). Syngulon has started to generate a patent portfolio of genetic technologies focusing on the control of industrial microrefineries to solve key issues:

1.      Genetic security

2.      Increase yield by industrial Genetic Bio-control

3.      Contamination prevention against microbial invaders

4.      Genetic safety (= Gene containment)